Elena Helman
Overview
Explore the profile of Elena Helman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
5235
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Si H, Kuziora M, Quinn K, Helman E, Ye J, Liu F, et al.
Clin Cancer Res
. 2020 Dec;
27(6):1631-1640.
PMID: 33355200
Purpose: Tumor mutational burden (TMB) has been shown to be predictive of survival benefit in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors. Measuring TMB in...
2.
Merino D, McShane L, Fabrizio D, Funari V, Chen S, White J, et al.
J Immunother Cancer
. 2020 Mar;
8(1).
PMID: 32217756
Background: Tumor mutational burden (TMB), defined as the number of somatic mutations per megabase of interrogated genomic sequence, demonstrates predictive biomarker potential for the identification of patients with cancer most...
3.
Aggarwal C, Thompson J, Chien A, Quinn K, Hwang W, Black T, et al.
Clin Cancer Res
. 2020 Feb;
26(10):2354-2361.
PMID: 32102950
Purpose: The role of plasma-based tumor mutation burden (pTMB) in predicting response to pembrolizumab-based first-line standard-of-care therapy for metastatic non-small cell lung cancer (mNSCLC) has not been explored. Experimental Design:...
4.
Lin K, Harrell M, Oza A, Oaknin A, Ray-Coquard I, Tinker A, et al.
Cancer Discov
. 2018 Nov;
9(2):210-219.
PMID: 30425037
A key resistance mechanism to platinum-based chemotherapies and PARP inhibitors in -mutant cancers is the acquisition of reversion mutations that restore protein function. To estimate the prevalence of reversion mutations...
5.
Helman E, Nguyen M, Karlovich C, Despain D, Choquette A, Spira A, et al.
Clin Lung Cancer
. 2018 Oct;
19(6):518-530.e7.
PMID: 30279111
Introduction: The genomic alterations driving resistance to third-generation EGFR tyrosine kinase inhibitors (TKIs) are not well established, and collecting tissue biopsy samples poses potential complications from invasive procedures. Cell-free circulating...
6.
Perry J, Kiezun A, Tonzi P, Van Allen E, Carter S, Baca S, et al.
Proc Natl Acad Sci U S A
. 2014 Dec;
111(51):E5564-73.
PMID: 25512523
Osteosarcoma is the most common primary bone tumor, yet there have been no substantial advances in treatment or survival in three decades. We examined 59 tumor/normal pairs by whole-exome, whole-genome,...
7.
Helman E, Lawrence M, Stewart C, Sougnez C, Getz G, Meyerson M
Genome Res
. 2014 May;
24(7):1053-63.
PMID: 24823667
Retrotransposons constitute a major source of genetic variation, and somatic retrotransposon insertions have been reported in cancer. Here, we applied TranspoSeq, a computational framework that identifies retrotransposon insertions from sequencing...
8.
Lawrence M, Stojanov P, Polak P, Kryukov G, Cibulskis K, Sivachenko A, et al.
Nature
. 2013 Jun;
499(7457):214-218.
PMID: 23770567
Major international projects are underway that are aimed at creating a comprehensive catalogue of all the genes responsible for the initiation and progression of cancer. These studies involve the sequencing...
9.
Carter S, Cibulskis K, Helman E, McKenna A, Shen H, Zack T, et al.
Nat Biotechnol
. 2012 May;
30(5):413-21.
PMID: 22544022
We describe a computational method that infers tumor purity and malignant cell ploidy directly from analysis of somatic DNA alterations. The method, named ABSOLUTE, can detect subclonal heterogeneity and somatic...
10.
Sindi S, Helman E, Bashir A, Raphael B
Bioinformatics
. 2009 May;
25(12):i222-30.
PMID: 19477992
Motivation: Structural variants, including duplications, insertions, deletions and inversions of large blocks of DNA sequence, are an important contributor to human genome variation. Measuring structural variants in a genome sequence...